EGFR and non-small cell lung carcinoma: Furthermore, DFS data does not necessarily translate into a longer OS, as demonstrated by the example of the CTONG1104 study investigating gefitinib (first-generation EGFR-TKI) as adjuvant therapy for 2 years vs. 4 cycles conventional adjuvant chemotherapy in stage II–IIIA completely resected NSCLC with EGFR mutation [8].